ASP-8062
Pharmaceutical compound
From Wikipedia, the free encyclopedia
ASP-8062, or ASP8062, is a GABAB receptor positive allosteric modulator which is under development for the treatment of alcoholism.[1][3][4] It was also under development for the treatment of fibromyalgia and opioid-related disorders, but development for these indications was discontinued.[1] The drug is taken orally.[1][2]
- None
| |
| Clinical data | |
|---|---|
| Other names | ASP8062 |
| Routes of administration | Oral[1] |
| Drug class | GABAB receptor positive allosteric modulator[2] |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | ~40–50 hours[2] |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C20H29N3O2S2 |
| Molar mass | 407.59 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
It shows analgesic and antiaddictive effects in animals.[4][5][6][7] In a polysomnography study, ASP-8062 dose-dependently enhanced slow wave sleep (SWS; deep sleep) without affecting REM sleep in humans.[8] It also dose-dependently increased growth hormone (GH) release.[8] The time to peak levels of ASP-8062 in humans is 1 to 4 hours and its elimination half-life is approximately 40 to 50 hours.[2]
Development
ASP-8062 is under development by Astellas Pharma in collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA).[1] As of June 2023, it is in phase 2 clinical trials for alcoholism.[1][4][9] The drug is the most advanced GABAB receptor positive allosteric modulator in clinical trials as of 2024.[4][9][6]